TRCT
MLYS icon

Tower Research Capital (TRC)’s Mineralys Therapeutics MLYS Stock Holding History

Tower Research Capital (TRC)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.4K Sell
1,944
-5,979
-75% -$164K ﹤0.01% 2694
2026
Q1 		$215K Buy
7,923
+7,403
+1,424% +$217K 0.01% 1561
2025
Q4 		$18.9K Sell
520
-2,851
-85% -$114K ﹤0.01% 3137
2025
Q3 		$128K Buy
3,371
+622
+23% +$13.5K ﹤0.01% 1807
2025
Q2 		$37.2K Buy
2,749
+1,575
+134% +$22.8K ﹤0.01% 3226
2025
Q1 		$18.6K Buy
1,174
+169
+17% +$1.94K ﹤0.01% 3042
2024
Q4 		$12.4K Sell
1,005
-1,669
-62% -$21.8K ﹤0.01% 3621
2024
Q3 		$32.4K Sell
2,674
-697
-21% -$8.44K ﹤0.01% 2961
2024
Q2 		$39.4K Buy
3,371
+3,076
+1,043% +$38.7K ﹤0.01% 3278
2024
Q1 		$3.81K Sell
295
-2,584
-90% -$31.9K ﹤0.01% 4787
2023
Q4 		$24.8K Sell
2,879
-7,181
-71% -$56.4K ﹤0.01% 3527
2023
Q3 		$95.7K Buy
10,060
+9,718
+2,842% +$127K ﹤0.01% 2010
2023
Q2 		$5.83K Sell
342
-1,156
-77% -$17.3K ﹤0.01% 4784
2023
Q1 		$23K Buy
+1,498
New +$25.2K ﹤0.01% 3289

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Tower Research Capital (TRC)'s MLYS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Mineralys Therapeutics (MLYS) stake by 75% in Q2 2026, selling an estimated $164K and leaving 1,944 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Tower Research Capital (TRC) first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $215K in Q1 2026. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Tower Research Capital (TRC) held 1,944 shares of Mineralys Therapeutics worth $52.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5,979 Mineralys Therapeutics shares in Q2 2026, an estimated $164K.
  • Mineralys Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2694 holding.
  • Tower Research Capital (TRC) first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Mineralys Therapeutics position peaked at $215K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.